** Shares of Moderna MRNA.O fall 3.28% to $32.48 premarket
** U.S. health officials are reevaluating a $590 million contract that was awarded to co for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources
** The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered Moderna's COVID vaccine, the report added
** The U.S. government awarded MRNA $590 million in January to advance the development of its bird flu vaccine
** Shares have fallen nearly 65% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.